Evonetix makes key appointments to support development of novel gene synthesis technology
- Posted on 18 September
CAMBRIDGE, UK, 18 September 2018 – EVONETIX LTD (‘Evonetix’), the company pioneering an innovative approach to scalable and high-fidelity gene synthesis, announced today that it has expanded its team three-fold, following a successful series A round of £9 million ($12.3M) to support the development of the Company’s technology.
The appointments include physicists, electrical, mechanical and software engineers, chemists and biologists, bringing the Company’s headcount currently to 34. Growth of Evonetix’s technical and scientific team is part of its strategy to revolutionise gene synthesis by developing a novel, silicon-based gene synthesis device that will deliver high-fidelity gene-length DNA at scale.
By directing the synthesis of DNA at many sites in parallel, followed by an integrated error-detection process throughout the assembly process, Evonetix’s platform facilitates the synthesis of high-fidelity, long DNA molecules at scale, including challenging sequences with high GC-content or repeats. The Company’s approach to gene synthesis has the potential to enable many applications in the rapidly growing field of synthetic biology, from the development of novel pharmaceuticals, to industrial biotech, renewable fuels, agriculture and potentially digital data storage.
Tim Brears, Evonetix CEO, said: “These appointments form part of our ambitious growth plans and mission to further advance our innovative and disruptive gene synthesis technology, to facilitate the rapidly growing field of synthetic biology, where scale and high fidelity will be essential. Following our recent fundraising, we’re investing in key technical and scientific roles as planned, and we are excited to welcome the new members of our multidisciplinary team.”For further information about Evonetix’s team, please visit: www.evonetix.com/full-team
Share this article:
People also read
Synthetic biology start-up Colorifix raises $3m Series A round to scale its revolutionary textile dyeing solution
Colorifix, a company that has developed the first commercial biological dyeing process, has raised a Series A round of $3 million from impact and stra...
Evonetix wins Best Emerging Synthetic Biology Company at the OBN Awards
London, UK, 12th October 2018 / Sciad Newswire / SynbiCITE would like to congratulate Evonetix on winning ‘Best Emerging Synthetic Biology Company’ at...
Addressing Global Challenges
Expert insights from SynbiCITE's leadership on the role of synthetic biology in solving some of the most significant challenges currently faced by our society